A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia
- PMID: 38546375
- DOI: 10.1002/ajh.27303
A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia
References
REFERENCES
- 
    - Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386‐2393.
 
- 
    - Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829‐2835.
 
- 
    - Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.
 
- 
    - Yu T, Wang L, Ni X, Hou Y, Liu X, Hou M. Orelabrutinib, a selective Bruton's tyrosine kinase (BTK) inhibitor in the treatment of primary immune thrombocytopenia (ITP). Blood. 2021;138(Supplement 1):3172.
 
- 
    - Kuter DJ, Efraim M, Mayer J, et al. Rilzabrutinib, an Oral BTK inhibitor, in immune thrombocytopenia. N Engl J Med. 2022;386(15):1421‐1431.
 
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
- Full Text Sources
- Medical
 
        